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Summary A recently developed enzyme assay, utilizing ['251]-iododeoxyuridine as substrate, and capable of
detecting normal levels of serum deoxythymidine kinase (s-dTk), was used in an investigation of sera from
155 untreated patients with non-Hodgkin's lymphoma (NHL). The patients were classified at the discovery of
disease, both according to spread (stages I-IV according to the Ann Arbor classification) and to tumour
histology (the Kiel classification). The results showed a significant correlation between s-dTk level and the
extent of disease, as well as to the malignancy; i.e. the more advanced the disease or the more aggressive the
tumour, the higher the s-dTk values. Greater than 100-fold increases in s-dTk levels were found in some
patients compared to those reported for healthy individuals. A high pretreatment level of s-dTk for patients in
stages III-IV correlated with a poor prognosis for the patient in terms of survival. This was consistent even
when only patients in stages III-IV with "high-grade" malignant lymphomas were included in the analysis.
Longitudinal studies of s-dTk levels in 19 NHL patients showed that s-dTk increases with progression of the
disease, decreases during successful therapy, and finally increases during relapse. It is concluded that s-dTk
could be used both as a prognostic marker and to monitor the effect of therapy in NHL patients.
Three different isoenzymes of deoxythymidine
kinase (dTk) (ATP:thymidine 5'-phosphotransferase
(EC 2.7.1.21)) have been found in human cells (Kit;
1979). One of these, dTK-F, the cytosolar dTk,
occurs in high amounts in dividing cells (stages
Gi -.S) and is more or less absent in resting
differentiated cells (Bello, 1974). For this reason
dTk activity has been studied in relation to tumor
cell growth, employing different animal systems
(Bresnick et al., 1969, 1971, Rothschild & Black;
1970, 1973). Studies of 23 matched human
neoplastic and normal tissue pairs showed higher
dTk activity in tumours, except for bronchogenic
carcinomas and hypernephromas (Gordon et al.,
1968). Recent reports have demonstrated enhanced
dTk-F levels in peripheral blood lymphocytes of
some patients suffering from non-Hodgkin's
lymphoma (NHL) or active chronic lymphocytic
leukaemia (Ellims et al., 1981a; Ellims, 1981; Kreis
et al., 1982). These investigators, although using an
enzyme assay with radiolabelled dT as substrate,
were able to find dTk-F in the serum of 26 patients
with advanced NHL. By comparing these patients
with other patients having mainly dTk-A (the
mitochondrial isoenzyme) levels a significant
difference in median survival time was found i.e.
dTk-F positive patients had a short survival time
(Ellims et al., 1981b).
An optimized dTk assay suitable for the
detection of viral dTk isoenzymes based on the use
of [12 1]-iododeoxyuridine (IUdR) as the substrate
has been presented (Gronowitz & Kdllander; 1980).
A different assay system, still based on the use of
[125I]-IUdR, as the substrate, optimized to measure
dTk-F was recently developed (Gronowitz et al.,
submitted). By the use of this method normal
serum-dTk levels (s-dTk) could be measured and
transiently enhanced s-dTk levels were found
during acute-convalescent stage of infections with
morbilli, rubella and different herpesviruses.
Elevated s-dTk levels, were also found to be
characteristic of pernicious anaemia and of different
malignancies, such as chronic granulocytic
leukaemia, acute myelocytic and lymphocytic
leukaemia, small cell lung cancer, and non-
Hodgkin's lymphoma (NHL) (Gronowitz et al.,
submitted).
The aim of the present study was to correlate
s-dTk levels of patients with NHL to other
parameters, such as spread, grade of malignancy,
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and to therapic effects, in order to evaluate s-dTK
as a prognostic and diagnostic serum marker.
Materials and methods
Enzyme assay
The assay utilizes [125I]-IUdR (final concentration
10-7 M, 130-160CimM)- 1, as substrate, and is
described in detail elsewhere (Gronowitz et al.,
submitted). This new assay system gives a linear
turnover of substrate for the cellular dTk-F for
more than 2h. In order to minimize fluctuations in
the assay, a biological control for the isotope was
utilized, and all values were recalculated to units
(Gronowitz et al., submitted). Under the conditions
used 1 unit of enzyme is equal to an enzyme
activity of 1.2 10 '" katal, and gives I1000cpm,
with the amount of isotope used. The average s-dTk
level in healthy subjects is estimated to be 2.5 units
l1l-' (s.d. 1.25) (Gronowitz et al., submitted). All
units given are calculated per yl serum.
Serum sampling
Blood samples were collected from 155 untreated
patients, diagnosed to have NHL, who were
referred to the University Hospital in Uppsala
between February 1979 and September 1981. The
mean age of the patients was 54 y (range, 16-83 y).
Sera, from patients receiving intermittent therapy,
used in longitudinal studies of s-dTk were collected
before chemotherapy. All sera were stored at
-20°C until analyzed.
Classification and staging ofpatients
Histopathological classification was made by Dr. C.
Sundstrom, Department of Pathology, Uppsala
according to the Kiel classification system (Gerard-
Marchant et al., 1974). In the original classification
there are 2 prognostic subgroups, but recently 3
prognostic subgroups were recognized in the region
studied (Glimelius & Sundstrom; 1982). These
results have been applied in the present
investigation. The distribution of the patients is
shown in Table I, which also gives the different
histological types of each group and their
abbreviations. The criteria for staging adopted at
the Ann Arbor symposium on Hodgkin's disease
was used (Carbone et al., 1971). The initial
evaluation included physical examination, complete
blood counts, urine analysis, measurement of the
erythrocyte sedimentation rate and serum
concentrations of uric acid, liver enzymes, and
bilirubin. Both sternal bone marrow aspiration and
iliac crest core biopsy were performed. Radiological
examinations comprised chest X-ray, and
computerized tomography of the abdomen. Further
ultrasound scanning of the abdomen was
performed. Lymphangiography was performed only
in a few patients. Restaging was performed after 6-
8 months of treatment. All examinations were
repeated if necessary, except lymphangiography.
Complete remission was defined as total
disappearance of the tumour for at least one
month, partial remission as regression of tumour
mass by >50%, and progressive disease as tumour
progression by >25%.
Table I Distribution of the histological subgroups according to the Kiel classification and the stage of
disease.
Abbreviation Stage: I II III IV
"High-grade" malignancy
Lymphoblastic (LB) 1 1 0 3
Immunoblastic (IB) 2 2 1 3
Centroblastic (CB) 13 3 2 21
Diffuse centroblastic-centrocytic (D CB-CC) 4 1 2 6
"Intermediate-grade" malignancy
Immunocytic (IC) 9 3 0 21
Centrocytic (CC) 0 0 0 1
Follicular and diffuse centroblastic-centrocytic (F+D CB-CC) 1 1 2 7
"Low-grade" malignancy
Lymphocytic (LC) 0 0 0 6
Follicular centroblastic-centrocytic (F CB-CC) 8 2 6 11
Unclassified 3 0 1 8
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Treatment ofpatients
All 54 patients in stage I and II (see Table I) were
irradiated with 40-45 Gy. Eight of these patients
took part in a separate clinical study and received
adjuvant chemotherapy with COP (cyclophos-
phamide, vincristine, prednisone) as described
by Bagley et al. (1972). The 101 patients in
stages III and IV (see Table I, for abbreviations)
were treated according to the following principles:
patients with CB, LB and IB were randomized and
treated either with CHOP (COP+doxorubicin), as
described by McKelvey et al. (1976), or MEV
(methotrexate, cyclophosphamide, vincristine), as
described by Lauria et al. (1978). All patients with
D CB-CC, F+D CB-CC, IC and patients with
LC or F CB-CC, who had progressive disease,
were randomized and treated with either COP or
intermittent Prednimustine (a chloroambucil ester
of prednisolone, AB Leo, Sweden), 150-200mg
daily for five days every fortnight. Patients were
treated with MEV or CHOP for 6 months, then
restaged, and if complete remission was found,
treatment was omitted. Patients in complete
remission after treatment with Prednimustine or
COP received maintenance treatment at successively
prolonged intervals for up to 2.5 y. Patients in
partial remission, progressive disease or relapse
received individual treatment. All patients could be
followed from admission to death or completion of
follow-up.
Statistical methods
The calculations of survival and the statistical
significance test (log rank test) were carried out
according to the method of Peto et al. (1977).
Results
Pretreatment s-dTk level in relation to stage
The distribution of pretreatment s-dTk levels, in
relation to stage of disease, is presented in Figure 1.
The mean pretreatment s-dTk value in stages I-11
was 4.7 units and in stages III-IV- 32.0 units. The
difference is highly significant (P<0.001).
Pretreatment s-dTk level in relation to histology
Pretreatment s-dTk levels found in patients of
stages III-IV distributed according to grade of
malignancy, are illustrated in Figure 2. The results
show that s-dTk level correlates with malignancy,
and a mean value of 4.6 units was found for
patients with "low-grade" malignancy, compared to
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Figure 1 s-dTk in 155 untreated patients with NHL
correlated to stage of the disease.
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Figure 2 s-dTk in 101 untreated NHL patients in
stages III-IV divided into three grades of malignancy.
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28.8 units for the "intermediate-grade" and 45.0
units for the "high-grade" group. The differences
between each group is significant at the P <0.01
level. Among the stage I-II patients with s-dTk >5
units (Figure 1), 6/8 had "high-grade" and the
other 2 "intermediate grade" malignancies.
Pretreatment s-dTk level in relation to survival
A discriminant analysis of pretreatment s-dTk levels
for patients in stages III-IV, in relation to survival
time was carried out. The results showed that the
best discriminating level was 10 units, giving a
highly significant difference in survival time
(P<0.001) between the 2 groups. The patients with
the low s-dTk values had an actuarial survival of
85% at the 32nd month compared to <30% for
those with levels above 10 units (Figure 3a). As it is
well known that the grade of malignancy influences
survival, we also compared s-dTK levels with
survival time for patients with "high grade"
malignancy in stages III-IV. A significant difference
was still found (P<0.02), with patients having
pretreatment s-dTk > 10 units dying sooner (Figure
3b).
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Pretreatment s-dTk level of stage I-IH patients in
relation to relapse
Of the patients in stage I and II, 8 received
adjuvant chemotherapy besides local radiotherapy,
and the remaining 46 local radiotherapy only. In
the latter group 8 had pretreatment s-dTk levels
>5 units, and 6 of them relapsed within a year. In
contrast, only 8 out of the other 38 patients, had a
recurrencewithinthesametime.The2patientswiththe
highest s-dTk levels, 45.4 and 23.3 units respectively,
rapidly sustained systemic spread during initial
radiotherapy, indicating an underestimation of the
staging.
S-dTk level in longitudinal studies of NHL patients
related to treatment and development ofdisease.
S-dTk was measured during the treatment of NHL
patients. For intermittently-treated patients the sera
were collected before therapy at each time point.
Representative examples of variations in s-dTk are
given for 19 patients in Figures 4-7, and the first
value always represents pretreatment s-dTk. Clinical
data for the 19 patients, such as age, sex, tumour,
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Figure 3 (a) probability of survival for 101 NHL patients in stages III-IV with pretreatment s-dTk < 10
units (0-0; n=50), and > 10 units (0-0; n=51). (Number in parenthesis indicates remaining individuals
at observation after 32 months). (b) Probability of survival for 38 NHL patients in stages III-IV with "high
grade" neoplasms. Pretreatment level of s-dTk <10 units (0-0; n=1), and > 10 units (0-0; n= 27).
(Number in parenthesis indicates remaining individuals at observation after 32 months).SERUM DEOXYTHYMIDINE KINASE IN NON-HODGKIN'S LYMPHOMA 491
Table 11 Clinical data from 19 NHL patients who were followed longitudinally with serial measurements of s-dTk.
Figure Patient Sex/Age Histology
Initial
Stage treatment
Response to initial
treatment
IV
IV
I
II
II IV
IV
IV
IV
IV
IV
IV
III
IV
IV
IV
IV
IV
IV
Splenectomy
Splenectomy
RT
RT
RT
COP
Prednimustine+COP
CHOP
COP
COP
Prednimustine
CHOP
MEV
MEV
MEV+CHOP
Prednimustine+COP
CHOP
COP
COP
MEV
Prednimustine
CHOP
CR
CR
CR
PD
PD
PD
PR
PR
CR
CR
CR
CR
PD
PD
PR
PR
CR
COMLA
CHOP
CHOP
= Cyclophosphamide, Vincristine, Prednisone
=Methotrexate, Cyclophosphamide, Vincristine
=Cyclophosphamide, Adriamycine, Vincristine, Prednisone
=Cyclophosphamide, Vincristine, Methotrexate with leucovorin rescue, Cytarabine
= a chlorambucil ester of prednisone
=Radiotherapy
=Complete remission
=Partial remission
=Stationary disease
=Progressive disease
=Follicular
=Diffuse
=Centroblastic
=Immunoblastic
=Centrocytic
histology, stage on admission, initial treatment,
response to treatment and relapse therapy, are
summarized in Table II. Figure 4 shows that a
rapid fall in s-dTk was observed after splenectomy
as examplified in 2 patients. Three patients in stage
I or II with low s-dTk, treated initially only with
local radiotherapy and having elevated s-dTk at
relapse are shown in Figure 5. All 3 received
chemotherapy during relapse, and in two of them
s-dTk was measured after chemotherapy was given.
Patient MO responded to the therapy and s-dTk
was found to decrease, whereas HH did not
respond and s-dTk remained unchanged.
The remaining 14 patients were all in stage III or
IV when therapy was started. Five of them did not
respond to the initial treatment, and, 3 died
without any improvement (Figure 6a); as seen in
Figures 6a and 7a, progression of the disease was
accompanied by increasing s-dTk. The other 2
responded and underwent temporary improvement
when given a different therapy; s-dTk mirrored this
clinical course by a temporary decrease followed by
continued increase (Fig. 7a).
Four patients were considered to be in partial
remission after 6 months of treatment, and their
s-dTk levels were found to decrease, but not to
normality (Figure 6b, and 2 patients in Figure 7b).
Two of these relapsed and increasing s-dTk levels
ensued (Figure 7b).
Finally, 5 patients went into complete remission,
which was followed by normalization of s-dTk
(Figure 6c, and patient GE in Figure 7b). Ope of
them relapsed (Figure 7b) and a high s-dTk level
was found.
Relapse
treatment
5
5
6
6
6
7a
7a
7a
7b
7b
7c
7c
7c
7c
8a
8a
8b
8b
8b
BB
AJ
KA
MO
HH
LJ
AM
AT
CJ
KL
LD
KE
LH
GT
OE
EM
AH
EL
GE
M 36
F 77
F 31
M 70
M 68
F 77
F 61
F 61
F 50
M 71
F 55
F 60
F 74
M 63
M 55
M 62
M 36
F 69
M 68
F+D CB-CC
IC
IB
IC
LB
IB
D CB-CC
CB
CC
F CB-CC
F CB-CC
CB
CB
IB
CB
Unclass.
CB
Unclass.
F+D CB-CC
Abbreviations
COP
MEV
CHOP
COMLA
Prednimustine
RT
CR
PR
SD
PD
F
D
CB
IB
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Figure 5 s-dTk in 3 patients with initial localized
NHL (stages I and II), who later relapsed. 1). Before
local radiotherapy 2). After local radiotherapy 3). At
systemic relapse 4). After the first treatment with
chemotherapy. M.O. responded, whereas H.H. did not.
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Figure 6 s-dTk in NHL patients. (a) patients with progressive disease, (b) two patien
remission, (c) four patients treated to complete remission.
nts treated to partialSERUM DEOXYTHYMIDINE KINASE IN NON-HODGKIN'S LYMPHOMA 493
A
300
200]
100
50
40
30
20
10
5.
4
3
2
o E.M.
* O.E.
B
*E.L.
a A.H.
*G.E.
0 1 2 3 4 5 6 0 3 6 9 12 15
Time (months)
Figure 7 s-dTk followed longitudinally in patients, where both progressive disease (a), and remission (b)
occur, (A) two patients with progressive disease, who after change of therapy were treated to partial remission
before the disease progressed again, (B) three patients treated to remission (A.H. and E.L. to partial, and
G.E. to complete remission). All of them later relapsed. A.H. responded transiently to further therapy.
Discussion
Despite information on histopathology, stage and
other clinical parameters it is often difficult to
predict the clinical course of lymphomas of the
non-Hodgkin's type. There is therefore a need for a
multiparametric approach to define subgroups of
patients with different clinical behaviour. Among
biochemical serum markers, the most important of
those previously reported are #2-microglobulin
(Child et al., 1980, Hagberg et al., In press) and
lactodehydrogenase (Ferraris et al., 1979, Schneider
et al., 1980).
By a recently developed method for
quantification of s-dTk in normal serum, variations
in s-dTk in NHL patients were detected. The results
showed that s-dTk levels in pretreatment sera
correlated with the spread of disease, i.e. most
patients in stages I and II had normal values,
whereas elevated levels, in some cases >100xthe
normal value, could be found in sera of patients in
stages III and IV. When patients in stages III-IV
were divided according to the malignancy of the
tumour, it was found that high s-dTk levels,
correlated with high malignancy. Discriminant
analysis of pretreatment s-dTk levels of patients in
stages 111-IV, relative to survival time, revealed two
groups which differed significantly in survival time.
The optimal discrimination level of s-dTk was
found to be 10 units, with the significant longer
survival associated with those having values <10
units. However it could be argued that patients in
stages III and IV comprise those with tumours of
low malignancy and others with "high grade"
malignant tumours. For this reason sera were
analysed from a group of patients in stages III and
IV who all had "high grade" malignant tumours.
The results still showed significantly different
survival times for those having s-dTk <10 units
compared to those having s-dTk >10 units.
Moreover, for stage I-II patients, who received only
radiotherapy, a higher relapse frequency was found
during the first year when the pretreatment s-dTk
level was >5 units. The method may thus be able
to identify those patients for whom local
radiotherapy cannot be considered sufficient. From
the results discussed above it was concluded that
pretreatment s-dTk values provide a useful
prognostic tool. The prognostic value of s-dTk
found in this study is in agreement with a previous
smaller study which used another method to
determine s-dTk (Ellims et al., 1981b).
Longitudinal studies of patients with low or high
pretreatment values showed that the s-dTk level
reflected the activity of the disease; i.e. the titres
decreased during tumour regression and increased
during tumour progression. For this reason s-dTk
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can be used to detect relapses. Patients with
therapy-resistant or only partially-responsive disease
had a persistent elevation of s-dTk. Since sera were
always collected before intermittent therapy was
administered the long term effects of treatment
were mirrored in the s-dTk level. However, the
short- to immediate-term effect of successful
chemotherapy on s-dTk, as indicated in preliminary
studies, is a transient rise (data not shown). The
utilization of dTk release as a direct marker for
therapic efficacy has been suggested previous from
cell cultures studies (Kessel & Wodinsky; 1970,
Taylor et al., 1981).
The origin of the elevated s-dTk is not yet
known. We have indicated elsewhere that the serum
enzyme is of cellular origin, and probably related to
the cytosolar dTk-F (Gronowitz et al., In press).
The enzyme is most likely released into the serum
upon the death of cells in a proliferating stage,
which seems to be a rare event in healthy
individuals. However, the s-dTk level can be
increased due to virus infections and pernicious
anaemia, but s-dTk is not a marker for non-specific
liver damage (Gronowitz et al., In press). This may,
however, be a rare complication since most viruses
which are known to give elevated s-dTk, are
confined to childhood.
The huge variation in s-dTk found in
pretreatment sera of NHL patients considered to
have the same clinical picture, could be due to
different amounts of dTk per cell in individual
tumours or to a higher turnover of the tumour
cells. This has to be investigated, as well as how
s-dTk expression relates to other better known
markers, such as /32-microglobulin and
lactodehydrogenase (studies in progress).
The findings reported in this communication
show that s-dTk is a prognostic tool and a valuable
marker in monitoring the course of the disease in
NHL patients. Further, the simplicity of the s-dTk
assay makes it suitable for widespread clinical use.
We are indebted to Dr. U. Pettersson for valuable
discussions and critical review of the manuscript. U.
Langstrom-Persson, E. Nilsson and K. Hjelmar
provided excellent technical assistance.
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